title: [Effect of antilipemic therapy on patients with diabetes mellitus and obesity].
abstract: Fibrates are hypolipemic agents used in noninsulin dependent diabetes mellitus (NIDDM) because these drugs have no influence on glycemia control. The efficiency of fenofibrate (Lipanthyl) was studied in a group of 22 subjects, 30-70 years, obese (body mass index-BMI over 30 kg/m2) or overweight (BMI = 28-30 kg/m2) with hypertension or/and diabetes. All the patients received 200 mg fenofibrate daily, for 6 month, and they had a hypocaloric diet. We measured seric lipids. The results were compared with a control group (20 normal subjects). Under treatment, atherogenic lipids (total cholesterol, LDL-cholesterol and triglycerides) had significantly decreased (p < 0.05) and antiatherogenic fraction (HDL-cholesterol) significantly increased (p < 0.05) compared to initial values. In the mean time, the BMI has significantly decreased under fenofibrate treatment, this body mass loss having a positive influence on lipid metabolism. We observed a better therapeutically response in obese patients vs. the overweight ones, probably due to a higher prevalence of the hypertension in the second subgroup. In conclusion fenofibrate is the drug which can be choose in diabetic dyslipidemia without cardiac disease.
authors.affiliation: Disciplina de Biochimie, Facultatea de Medicină, Universitatea de Medicină şi Farmacie Gr.T. Popa Iaşi.
authors.forename: Didona
authors.initials: D
authors.lastname: Ungureanu
authors.forename: Adorata
authors.initials: A
authors.lastname: Coman
authors.forename: Mihaela
authors.initials: M
authors.lastname: Maftei
authors.forename: Irina
authors.initials: I
authors.lastname: Popovici
authors.forename: Anca
authors.initials: A
authors.lastname: Artenie
authors.forename: R
authors.initials: R
authors.lastname: Artenie
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D011345:Fenofibrate